The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
Open accessAbstract
Introduction Retrospective studies have shown immune-related adverse events (irAEs) to be associated with better prognosis. However, no prospective clinical trials have been conducted, and little is known regarding the association between irAEs and the outcome of patients with NSCLC after treatment with immunotherapy.Methods We conducted a prospective cohort study of patients with advanced NSCLC who were treated with nivolumab between January and December 2016. The association between clinical outcome and irAEs 2 to 6 weeks after commencement of nivolumab treatment was investigated. IrAEs were assessed by at least three independent medical professionals.Results A total of 43 patients were enrolled, including 19 patients with irAEs 2 weeks after commencement of nivolumab treatment. Common irAEs included rash, pyrexia, and diarrhea. Programmed cell death ligand 1-positive tumor cell expression was not significantly different between patients with and without irAEs. The objective response and disease control rates were higher in patients with irAEs than in those without irAEs (37% versus 17% and 74% versus 29% [p = 0.17 and p < 0.01], respectively]). Patients with irAEs were associated with a significantly longer median progression-free survival than those without (6.4 months [95% confidence interval: 2.5-not reached] versus 1.5 months [95% confidence interval: 1.2-2.3] [p = 0.01]). These findings were comparable to those for patients with and without irAEs 6 weeks after commencement of nivolumab treatment.Conclusions Early irAEs are associated with a better outcome after treatment with immunotherapy. We predicted responses to nivolumab by using early irAEs. Further research is needed to elucidate the mechanisms of these associations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both ORR and DCR were higher in patients who experienced IRAEs at ≤2 weeks and ≤ 6 weeks compared to those who did not experience them.”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.5.584 · Cited by 3,991
Postmus, P. E., Brambilla, E. M., Chansky, K., Crowley, J. J., Goldstraw, P. G., Patz, E. F., & Yokomise, H. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31811f4703 · Cited by 1,593
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–377 of 377
Immune Checkpoint Inhibitor-Induced Insidiously Progressive, Fatal Interstitial Lung Disease
Kanaji, N., Watanabe, N., Inoue, T., Mizoguchi, H., Komori, Y., Ohara, Y., & Kadowaki, N. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15030115 · Cited by 3
Hu, X., Rodday, A. M., Gurinovich, A., Pan, S. S., Salei, Y. V., Lin, J. H., Byrne, M. M., Cao, Y., Pai, L. H., & Parsons, S. K. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2488728 · Cited by 3
Talab, T. J., Shafi, F. A. A., & Jasim, S. M. (2025) · World Academy of Sciences Journal · doi:10.3892/wasj.2025.370 · Cited by 3
Ye, Z., Zheng, S., Chen, J., Zhang, Y., Yang, S., Hong, Y., Yang, H., Xuan, Z., & Zhao, Q. D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108738 · Cited by 2
Hayashi, H., Nishio, M., Akamatsu, H., Goto, Y., Miura, S., Gemma, A., Yoshino, I., Misumi, T., Kijima, T., Takase, N., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0212 · Cited by 5
Molina‐Cerrillo, J., Roviello, G., Bourlon, M. T., Študentová, H., Fiala, O., Cerbone, L., Kucharz, J., Ansari, J., Zeppellini, A., Taha, T., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70228 · Cited by 3
Ashinuma, H., Mizuno, S., Yoshida, Y., & Shingyoji, M. (2019) · Case Reports in Oncological Medicine · doi:10.1155/2019/4836404 · Cited by 3
Yamaura, T., & Suzuki, H. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.021 · Cited by 3
Zhao, J., Quan, X., Yu, L., Ni, B., Xing, X., & Liu, G. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2476332 · Cited by 2
Rudzińska, A., Juchaniuk, P., Oberda, J., Krukowska, K., Krzyśkowska, S., Kuchta, E., Rodzajewska, A., Janiszewska, M., Machulska-Ciuraj, K., & Szklener, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1527103 · Cited by 2
Keller, D. M., Żarczyński, D., Rybacka, A., & Kuźnar-Kamińska, B. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1672093 · Cited by 2
Refractory hypotension with fever revealing checkpoint inhibitor-induced hypophysitis
Plaçais, L., Hau, E., Delyon, J., Azoulay, É., Gautier, J., Lebbé, C., & Baroudjian, B. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000517 · Cited by 2
Kapoor, A., Noronha, V., Patil, V. M., Joshi, A., Menon, N. S., Kumar, A., Mahajan, A., Janu, A., Kumar, R., & Prabhash, K. (2022) · South Asian Journal of Cancer · doi:10.1055/s-0041-1740243 · Cited by 2
Nakashima, K., Demura, Y., Akai, M., & Ishizuka, T. (2021) · Cureus · doi:10.7759/cureus.16177 · Cited by 2
How to manage side effects of immunotherapy
Kopecký, J., & Kubeček, O. (2020) · Onkologie · doi:10.36290/xon.2020.049 · Cited by 2
Relationship of Hypothyroidism and Immune Response to Pegylated IL-10/nivolumab
Albrethsen, M., Creeden, J. F., Morand, S. M., DeBiase, J. M., Berry, B. M., Stanbery, L., Edelman, G. M., & Nemunaitis, J. J. (2020) · Immunotherapy · doi:10.2217/imt-2020-0016 · Cited by 2
Matsubara, T., Yamaguchi, M., Jinnouchi, M., Takamori, S., Fujishita, T., Toyozawa, R., Ito, K., Shimokawa, M., Seto, T., & Okamoto, T. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03478-2 · Cited by 2
Tatsumi, A., Maekawa, Y., Komori, Y., Yamamoto, K., Hamaguchi, T., Takahashi, K., & Kunimasa, J. (2020) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.46.331 · Cited by 2
A Case of Nivolumab-induced Severe Neutropenia with Stomatitis, Enteritis and Liver Dysfunction
Saijo, T., Tanaka, A., Ito, T., & Ikeda, N. (2018) · Haigan · doi:10.2482/haigan.58.996 · Cited by 2
Wang, L., Abbas, M., Wang, F., Mikrani, R., Li, X., Fan, L., Wang, X., & Shi, M. (2020) · Current Medicine Research and Practice · doi:10.1016/j.cmrp.2020.05.004 · Cited by 2
Lu, J., Zhu, J., & Jiang, G. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073267261231106093845 · Cited by 1
A Case of Pseudoprogression in Lung Adenocarcinoma Treated with Nivolumab
Nakamura, A., Aiba, T., Kawana, S., Saito, R., Toi, Y., & Sugawara, S. (2019) · Haigan · doi:10.2482/haigan.59.60 · Cited by 1
Yang, Z., Luo, Y., Lu, R., Liu, X., Liu, H., Liu, S., Huang, C., Tian, J., & Zhang, L. (2025) · Current Oncology · doi:10.3390/curroncol32040195 · Cited by 1
Imasato, Y., Kanda, H., Ishizaki, N., Sasaki, K., & Fukumoto, Y. (2025) · Haigan · doi:10.2482/haigan.65.164 · Cited by 1
Liu, Y., Zhang, T., Gao, Y. J., Qu, Y., Lu, B., Zhang, H., Wang, Q., Li, J., Hu, F., & Li, B. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.11.02 · Cited by 1
Okamoto, I., Sato, H., & Tsukahara, K. (2020) · Auris Nasus Larynx · doi:10.1016/j.anl.2020.02.018 · Cited by 1
RetractedGoto, Y., Yoh, K., Kato, T., Hosomi, Y., Usui, K., Fukui, T., Hirano, K., Tanaka, H., Taguri, M., & Kunitoh, H. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac159 · Cited by 1
Li, L.-Z., Lin, S., Wu, L., Chen, T., Zhuang, J.-N., Lai, H., Liang, Z., Zhu, W.-S., Li, W., Tang, L., et al. (2023) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001497 · Cited by 1
Management of Adverse Events Induced by Immune Checkpoint Inhibitors in Lung Cancer Treatment
Miura, S., 磯貝佐知子, Yoshino, M., Baba, J., Kajiwara, T., Koyama, K., Takenouchi, T., Tani, N., & Tanaka, H. (2019) · Haigan · doi:10.2482/haigan.59.231
The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer
Andrews, S., & Davies, M. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-16550-5_7
Tsutsumi, S., Ohkubo, Y., Takizawa, A., Yasui, M., Noguchi, G., Umemoto, S., Kato, T., & Kishida, T. (2019) · The Japanese Journal of Urology · doi:10.5980/jpnjurol.110.124
Nivolumab 投与を行った再発・転移頭頸部扁平上皮癌症例の検討
紘一郎, 中., 隆治, 安., 佳江, 高., 龍之介, 古., 高裕, 若., & 尚志, 中. (2019) · 耳鼻と臨床 · doi:10.11334/jibi.65.6_175
Ma, Y., Ma, X., Wang, J., Wu, S., Wang, J., & Cao, B. (2021) · Research Square · doi:10.21203/rs.3.rs-484073/v1
Adda, L., Batteux, B., Saidak, Z., Poulet, C., Arnault, J., Chauffert, B., & Séjourné, A. (2021) · Revue du Rhumatisme · doi:10.1016/j.rhum.2021.10.564
Shantzer, L., Dougherty, S. C., Novicoff, W. M., Melson, J. W., Reed, D. R., Lynch, A. C., Gentzler, R. D., & Hall, R. D. (2021) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2021-sitc2021.803
Diker, Ö. (2022) · International Journal of Hematology and Oncology · doi:10.4999/uhod.226042
Anti-neoplastic Immunomodulatory Treatments and the Pituitary
Rengarajan, M., & Faje, A. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-99918-6_25
Bargieł, J., Cabaj, J., Chmielewska, I., Wójcik-Superczyńska, M., & Milanowski, J. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2022.12.09.099
Sayer, M. (2023) · Chapman University Digital Commons (Chapman University) · doi:10.36837/chapman.000424
Mechanisms of Immunological Toxicity in Cancer Immunotherapy with Checkpoint Inhibitors
Polaczek, M. M., & Piotr, R. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_360-1
Wang, N., Xiao, R., & Liu, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-3175459/v1
Role of biomarkers in assessing response to immune checkpoint inhibitors in cancer treatment
Jain, K. M., Ganguly, N. K., & Aggarwal, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95114-2.00023-6
Huang, A., Xu, Y., Zang, X., Wu, C., Gao, J., Sun, X., Xie, M., Ma, X., Deng, H., Song, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14702271
Biomarkers for response to immune checkpoint inhibitors in metastatic melanoma
Wind, T. T. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.1065420649
Morikawa, R., Nitta, K., Yasuda, S., Kano, Y., Noji, R., Aoyama, S., Sato, S., Ikeda, S., Okamoto, R., Nagata, M., et al. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2443955
Guo, X., Zhang, H., Shi, Y., He, Q., Liu, A., Zeng, Z., Wang, J., Song, W., Zhang, T., Ding, C., et al. (2025) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-271
Nagai, T., Akamatsu, H., Takase, E., Murakami, E., Sugimoto, T., Shibaki, R., Hayata, A., Shimizu, T., Nakanishi, M., Koh, Y., et al. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70090
Chalif, J., Morton, M. A., McLaughlin, E. M., Gonzalez, A., Fulton, J., Sciuva, J., Marcu, I., Bixel, K. L., Cohn, D. E., Cosgrove, C. M., et al. (2025) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2025.101782
Ouyang, T., Zhang, F., Yang, Y. P., Luo, T., Chen, A., Han, N., Qian, J., Chu, X., Chen, C., & Yang, M. Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-14559-1
Okamoto, K., Kikuchi, D., Yamashita, S., Kinowaki, K., Suzuki, Y., & Hoteya, S. (2025) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-025-02207-x
Sakurai, K., Imaue, S., Ikeda, A., Sakurai, A., Tachinami, H., Takatsuka, D., Fujiki, M., & Yamada, S. (2025) · Journal of Oral and Maxillofacial Surgery Medicine and Pathology · doi:10.1016/j.ajoms.2025.09.015
Zhang, M., Li, Y., Guo, L., Lin, H., Cao, X. Q., Ding, Z., Han, Y., & Lu, H. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2587377
Molina‐Cerrillo, J., Roviello, G., Fiala, O., Taha, T., Buti, S., Rizzo, M., Massari, F., Monteiro, F. S. M., & Santoni, M. (2025) · International Journal of Cancer · doi:10.1002/ijc.70289
Hosoya, K., Fujimoto, D., Morimoto, T., Kumagai, T., Tamiya, A., Taniguchi, Y., Yokoyama, T., Ishida, T., Matsumoto, H., Hirano, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361537
Self-citationTakada, K., Shimokawa, M., Takamori, S., Shimamatsu, S., Hirai, F., Tagawa, T., Okamoto, T., Hamatake, M., Tsuchiya‐Kawano, Y., Otsubo, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19728038
Takada, K., Shimokawa, M., Takamori, S., Shimamatsu, S., Hirai, F., Tagawa, T., Okamoto, T., Hamatake, M., Tsuchiya‐Kawano, Y., Otsubo, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19728041
Yang, F., Shay, C., Abousaud, M. I., Tang, C., Li, Y., Qin, Z., Saba, N. F., & Teng, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26559209
Yang, F., Shay, C., Abousaud, M. I., Tang, C., Li, Y., Qin, Z., Saba, N. F., & Teng, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26559206
Liu, C., Piao, J., & Shang, Z. (2021) · Figshare · doi:10.6084/m9.figshare.14253857
Hosoya, K., Fujimoto, D., Morimoto, T., Kumagai, T., Tamiya, A., Taniguchi, Y., Yokoyama, T., Ishida, T., Matsumoto, H., Hirano, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361531
Self-citationHosoya, K., Fujimoto, D., Morimoto, T., Kumagai, T., Tamiya, A., Taniguchi, Y., Yokoyama, T., Ishida, T., Matsumoto, H., Hirano, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361534
Self-citationSanto, G., Cucè, M., Restuccia, A., Del Giudice, T., Tassone, P., Cicone, F., Tagliaferri, P., & Cascini, G. L. (2024) · Figshare · doi:10.6084/m9.figshare.27049000
Mechanisms of Immunological Toxicity in Cancer Immunotherapy with Checkpoint Inhibitors
Polaczek, M. M., & Piotr, R. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_360
Sakaki-Maeda, Y., Sakata, S., Iyama, S., Saruwatari, K., Yusuke, T., & Sakagami, T. (2025) · Haigan · doi:10.2482/haigan.65.1027
Fortes-González, M. S., Blanco, S. V., Herrero-Poch, L., Couto, L. S., & Cercós-Lletí, A. C. (2026) · Farmacia Hospitalaria · doi:10.1016/j.farma.2026.03.009
Yamaguchi, T., Shimizu, J., Matsuzawa, R., Shimomura, K., Watanabe, N., Horio, Y., & Fujiwara, Y. (2026) · BMC Cancer · doi:10.1186/s12885-026-15989-1
Zhao, L., Li, F., Zhu, Z., Zhao, J., Zhang, P., Ma, Y., & Shen, F. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109422
Temperature Dependent Motions of N ‐Terminal Loop in PD ‐1 Determine the Affinity Towards N ivolumab
Karbalaeimahdi, M., Marcelina, C. D. C., & Stan, R. C. (2026) · Journal of Molecular Recognition · doi:10.1002/jmr.70039
Li, X., Zhang, F., & Xu, X. (2026) · Discover Oncology · doi:10.1007/s12672-026-05354-w
Nomura, Y., Wada, Y., Sasaki, S., Ikeda, T., Ryu, T., & Takami, Y. (2026) · Journal of Medical Case Reports · doi:10.1186/s13256-026-06037-4
Fortes-González, M. S., Blanco, S. V., Herrero-Poch, L., Couto, L. S., & Cercós-Lletí, A. C. (2026) · Farmacia Hospitalaria · doi:10.1016/j.farma.2026.05.002
Kwiatkowska, N. M., Gelibter, A., Gabryel, P., & Piwkowski, C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15135009
Lin, S.-S., Hsu, P.-S., Lai, H.-C., Liu, J., & Cheng, W.-P. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1957383
Fan, J., Chen, D., & Jia, L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1948772
Metadata
- Authors
- Teraoka, S., Fujimoto, D., Morimoto, T., Kawachi, H., Ito, M., Sato, Y., Nagata, K., Nakagawa, A., Otsuka, K., Uehara, K., Imai, Y., Ishida, K., Fukuoka, J., & Tomii, K.
- Affiliations
- Kobe City Medical Center General Hospital (JP)
- Hyogo Medical University (JP)
- Nagasaki University Hospital (JP)
- Corresponding author
- Fujimoto, Daichi
- ORCID
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 12
- Issue
- 12
- Pages
- 1798-1805
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2754877046
- Cited by
- 375
- References
- 26
- Citations by year
- 2026: 10 · 2025: 25 · 2024: 29 · 2023: 29 · 2022: 44 · 2021: 68 · 2020: 79 · 2019: 67 · 2018: 22 · 2017: 2
- FWCI
- 20.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- immune-related adverse events, nivolumab, non-small cell lung cancer, immune checkpoint inhibitors, immunotherapy response prediction, progression-free survival, PD-L1 expression, rash, fever, diarrhea, objective response rate
- MeSH terms
- Nivolumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Middle Aged, Prospective Studies, Cohort Studies, Treatment Outcome, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
